Posts
- Tue Mar 20, 2012 Webinar: Challenges in Early Comparability Assessment of Biosimilars (February 1, 2010)
- Tue Apr 24, 2012 Webinar: Discerning Early Clinical Signals of Efficacy for Treating Respiratory Diseases (March 28, 2010)
- Celerion acquires early stage clinical research operations from MDS Pharma Services (March 29, 2010)
- Celerion launches new Hybrid ECG Core Lab for Phase I clinics (June 2, 2010)
- Celerion launches electronic laboratory notebook, achieving major milestone toward 100% paperless laboratories (November 12, 2010)
- Celerion and BryanLGH Health System Form Alliance to Provide Dedicated Hospital Beds for Phase I Studies (December 9, 2010)
- Celerion adds USP Clean Room, enabling efficient execution of microtracer and microdosing studies (March 2, 2011)
- Celerion recognized as member of the UK Respiratory Therapeutic Capability Cluster (March 28, 2011)
- Member of UK Respiratory Therapeutic Capability Cluster (March 28, 2011)
- Celerion awarded prestigious LEED® Green Building Certification (May 26, 2011)
- Celerion receives ANVISA certification (June 9, 2011)
- Celerion announces highly automated ECG analysis enabling data delivery within 37 days from first patient dosed (June 20, 2011)
- Celerion achieves major milestone of successfully analyzing over 25,000 platelet aggregation samples (June 21, 2011)
- Celerion appoints Dr. Raymond Farmen as Vice President of Global Bioanalytical Services (June 29, 2011)
- Celerion receives license enabling Investigational Medicinal Products (IMPs) to be imported directly to their GMP-licensed facility (September 7, 2011)
- Celerion scientist proud recipient of Scientific and Technological Achievement Award (STAA) from EPA (January 11, 2012)
- Celerion First Early Stage Contract Research Organization to Adopt a Participant Verification System to Improve Participant Safety and Data Quality (February 2, 2012)
- Celerion and Ricerca Biosciences announces “The Biosimilars Alliance” to offer clients a more effective development path for biosimilars (February 29, 2012)
- Celerion announces expanded state-of-the-art ADME Suite in its Lincoln, Nebraska USA facility (May 17, 2012)
- Celerion is the First CRO Headquartered in the USA to Receive Full Accreditation from AAHRPP (September 17, 2012)
- Celerion Builds on Respiratory Capabilities With the Addition of an On-site Bronchoscopy Suite (January 9, 2013)
- Types and Features of NDA Enabling (February 25, 2013)
- Celerion appoints Dr. Bruce Morimoto as Executive Director, Applied Translational Medicine (May 21, 2013)
- Celerion Expands Belfast Facility with Containment Room to Enable Live Biologics and Vaccine Studies (June 4, 2013)
- Celerion Appoints Clayton Dehn as Executive Director, Metabolic Diseases (November 5, 2013)
- Celerion Appoints John Horkulak as Executive Director, Eurasian Site Operations (December 5, 2013)
- Celerion Celebrates 80 Years of Conducting Business at Global Headquarters in Lincoln, Nebraska (December 17, 2013)
- Celerion Opens Operations in South Korea at Seoul National University Hospital Clinical Trial Center (March 4, 2014)
- Celerion and Korean Drug Development Fund Form Collaboration to Strengthen Early Phase Clinical Research in South Korea (May 28, 2014)
- Celerion Selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium for The Beta Cell Project (June 11, 2014)
- Celerion Appoints Dr. Robert Lester as Chief Cardiologist, Global Medical Director of Cardiac Safety Services (June 16, 2014)
- Celerion Expands Ophthalmological Capabilities to Patient Populations in Collaboration with Queen’s University, Belfast (September 30, 2014)
- Celerion Announces Membership into the Cardiac Safety Research Consortium (CSRC) (October 15, 2014)
- Celerion Completes Recapitalization Through Investment by MTS Capital Health Partners (October 29, 2014)
- Celerion Expands its Cell-Based Assays Capabilities in Global Bioanalytical Services (November 3, 2014)
- Assign Clinical Research Joins Celerion (January 11, 2016)
- Celerion Recognized by Biopharmaceutical Clients as a Leader in Contract Research Quality Benchmarking Survey (May 26, 2016)
- Supporting the Next Major Health Epidemic (August 19, 2016)
- Newsletter: Q4 2016 (October 1, 2016)
- Celerion Named Best Translational Clinical Pharmacology Company 2016 (October 5, 2016)
- Celerion Announces Celexus as a Premier Safety Reporting Tool for Phase I Clinical Trials (November 17, 2016)
- Newsletter: Q1 2017 (January 1, 2017)
- Celerion Appoints Dr. Marc Hoffman as Chief Medical Officer (February 22, 2017)
- Celerion Implements Biometric Fingerprint Technology and Marks Five-Year Anniversary with Verified Clinical Trials (March 14, 2017)
- Newsletter: Q2 2017 (April 1, 2017)
- Celerion Receives a 2017 CRO Leadership Award in Multiple Categories for Clinical Research Excellence (June 19, 2017)
- Newsletter: Q3 2017 (July 1, 2017)
- Newsletter: Q4 2017 (October 1, 2017)
- Prediabetes, the New Normal in Early Clinical Research (November 7, 2017)
- Newsletter: Q1 2018 (January 1, 2018)
- Celerion Creates a Fully Automated, Early Development Clinical Trial Data Management Platform (January 16, 2018)
- Industry Leading Nicotine Researcher Joins Celerion Research Team (January 23, 2018)
- Newsletter: Q2 2018 (April 1, 2018)
- Biopharmaceutical Industry Recognizes Celerion as a Leading Contract Research Organization (April 3, 2018)
- Know Your Numbers Campaign (April 9, 2018)
- The Next Frontier of Pharmacology: Micro Drug Delivery (July 9, 2018)
- Newsletter: Q3/Q4 2018 (September 1, 2018)
- Entering the NASH Race: Tips for Early Clinical Development (October 15, 2018)
- Innovations in COPD – A Breath of Fresh Air (January 25, 2019)
- Newsletter: Q2 2018 (March 7, 2019)
- Newsletter: Q1 2019 (March 7, 2019)
- Celerion Recognized as a Leading Contract Research Organization for the 4th Consecutive Year (March 27, 2019)
- Backing the Biosimilar Boon (July 2, 2019)
- Newsletter: Q2 2019 (July 11, 2019)
- Celerion Celebrates 50th Anniversary of First Clinical Trial (July 17, 2019)
- NASH Pathway to Approval – Light at the End of the Tunnel (December 10, 2019)
- Newsletter: Q3/Q4 2019 (December 17, 2019)
- Celerion Expands Clinical Research to Nebraska Innovation Campus (February 13, 2020)
- Celerion Celebrates a Decade of Translating Science Into Medicine (March 10, 2020)
- COVID-19 Vaccines in Development (March 19, 2020)
- Pharmabiotics – Spreading Culture to Therapeutic Drugs (April 1, 2020)
- Capturing the Cytokine Storm: Using Biomarkers in COVID-19 Trials (April 27, 2020)
- COVID-19, Kawasaki and the Cytokine Storm (June 2, 2020)
- Celerion Expands HRMS Metabolite Identification Capabilities for Full Service Metabolism Offering (June 8, 2020)
- Open for Business: Early Phase Clinical Drug Development during the COVID-19 Pandemic (June 18, 2020)
- Celerion Recognized as 2020 CRO Leadership Champion for Reliability and Receives CRO Leadership Award for Capabilities, Compatibility, Expertise, and Quality (June 19, 2020)
- Celebrating a Decade of Biosimilars Development (June 30, 2020)
- The Platforms and Promise of COVID-19 Vaccines (July 7, 2020)
- Leveraging Innovative Technologies to Access Better Data More Efficiently and Cost-Effectively (July 8, 2020)
- A Decade of Innovative Technology to Accelerate Drug Development (August 4, 2020)
- Human Trials For Lyme Disease Shot Kickoff In Nebraska (April 7, 2021)
- Is Age Just a Number? Clinical Drug Development in Older Adults (April 19, 2021)
- Celerion Receives CRO Leadership Award for 6th Consecutive Year (June 1, 2021)
- Tackling the Complexity of Complex Generic Drug Development (June 8, 2021)
- Women in Leadership Spotlight: Michelle Combs (July 23, 2021)
- Women in Leadership Spotlight: Zori Cheshmedzhieva (October 4, 2021)
- Celerion Expands Early Phase Clinical Pharmacology Units (March 8, 2022)
- Celerion Announces Investment in ADME Suite of Services (April 6, 2022)
- CRO Leadership Award Goes to Celerion for a 7th Consecutive Year (June 15, 2022)
- Adaptive Trial Designs (June 29, 2022)
- Celerion Expands Its Service Offering to Include GLP/GCP Compliant Molecular and Cell Biology Testing (November 10, 2022)
- Celerion Receives a 2023 CRO Leadership Award in All Categories for the Eighth Year Running (May 10, 2023)
- Celerion Achieves Milestone With CLIA Certification for Its Bioanalytical Laboratory, Expanding Capabilities in Clinical Trials and Diagnostic Testing (February 6, 2024)
- 12 Questions to Help Guide Renal Impairment PK Study Design (March 26, 2024)
- Jo Goodman Joins Celerion as Vice President of Bioanalytical Services (May 7, 2024)
- Key Clinical Pharmacology Studies to Support Biologic Drug Regulatory Submission (May 22, 2024)
- Celerion Honored With Prestigious CRO Leadership Award for Ninth Consecutive Year (June 5, 2024)
- Celerion’s US Pharmacies Expand On-Site Services, Ensure cGMP FDA Compliance for Phase 1 Investigational Drugs (July 17, 2024)
- How Healthy Volunteer Studies can Accelerate Oncology Drug Development (September 11, 2024)
- GLP-1 Agonist-Induced Delayed Gastric Emptying – A Clinical Pharmacology Perspective (November 5, 2024)
- Celerion Pledges Commitment to the Science-Based Targets Initiative (SBTi) Net-Zero Standard (December 4, 2024)
- Celerion Expands UK Phase 1 Clinical Research Operations With New Agreement to Relocate to Queen’s University Belfast’s iREACH Health – Clinical Research Innovation Center (February 19, 2025)
- Reframing the Definition of Obesity (February 24, 2025)
- Ruling the Future: How the ACLA’s LDT Court Victory and Europe’s IVDR Are Shaping Bioanalytical Laboratories (April 3, 2025)
- FDA Endorses Human-Relevant Nonclinical Models: A Welcome Shift for Monoclonal Antibody Development (April 17, 2025)
- Smarter, Faster, Safer: Celerion Unveils Major Upgrade to LabNotes Bioanalytical Software (April 30, 2025)
- Rethinking Drug Development: The Role of Model-Informed Approaches in Advancing Cell and Gene Therapies Without Animal Testing (May 1, 2025)
- Celerion Launches Enhanced Version of Labnotes Bioanalytical Data Management Software (May 6, 2025)
- The Rising Tide of Weight Reduction Therapies (May 28, 2025)
- PBMCs or Whole Blood? Strategic Applications in Phase I Studies (August 28, 2025)
- Celerion Earns AAHRPP Full Reaccreditation for Five Years, Strengthening Commitment to Ethical Research Practices (October 9, 2025)
- Celerion Welcomes Dr. Steven Evans as Senior Cardiologist to Enhance Cardiovascular Safety in Clinical Trials (November 20, 2025)
- The Resurgence of Antibody Drug Conjugates: How ADCs are taking over oncology (again) and what we’ve learned about creating bioanalytical methods to support preclinical and clinical success. (February 26, 2026)
- Cocktail DDI Studies: Myths vs. Facts (May 11, 2026)
- Celerion Expands Zurich Bioanalytical Laboratory to Meet Growing Market Demand (June 25, 2026)
- When to Run a UGT-Mediated DDI Trial—and Why It Matters Clinically (August 20, 2026)
- New FDA Hepatic Impairment Guidance: What It Means for Your Next Dedicated Study (September 14, 2026)
- Signal to Noise versus Titer: Is it time to adopt a new paradigm for clinical immunogenicity assessment? (September 28, 2026)
- Integrating Bioanalysis: How Emerging Modalities are Changing Our Approach to Bioanalytical Testing Strategies (November 3, 2026)
Pages
- Home (September 19, 2017)
- Contact (September 19, 2017)
- Accessibility (June 6, 2019)
- Privacy Policy (May 20, 2024)
- About (November 12, 2025)
- Environmental, Social, and Governance (ESG) Initiatives (November 12, 2025)
- Leadership Team (November 12, 2025)
- Our Global Locations (November 12, 2025)
- Blog (November 12, 2025)
- Events (November 12, 2025)
- Participant Recruitment (November 12, 2025)
- News (January 21, 2026)
- Scientific Dinner Talk, Tuesday, 9/15, 6:30pm – Integrated Bioanalysis: Reshaping Traditional Approaches for Complex Modalities (July 29, 2026)
- Sites (November 12, 2025)
- Services (November 12, 2025)
- Early Phase Clinical Services (November 12, 2025)
- Bioavailability/Bioequivalence (November 12, 2025)
- Drug-Drug Interaction (DDI) (November 12, 2025)
- Single Ascending Dose/Multiple Ascending Dose (November 12, 2025)
- Food Effect Studies (November 12, 2025)
- Thorough QT (TQT) Studies (November 12, 2025)
- Radiolabeled (ADME) Studies (November 12, 2025)
- Pharmacodynamic (PD) Studies (November 12, 2025)
- Solutions (November 12, 2025)
- Bioavailability/Bioequivalence-TEST (January 22, 2026)
- Global Clinical Development (November 12, 2025)
- Drug Development & Regulatory Affairs Services (November 12, 2025)
- Monitoring & Project Management Services (November 12, 2025)
- Bioanalytical Science Services (November 12, 2025)
- Pharmacokinetics (November 12, 2025)
- Immunogenicity (November 12, 2025)
- Biomarkers (November 12, 2025)
- Biosimilars (November 12, 2025)
- Gene Therapy (November 12, 2025)
- Metabolite Identification and Profiling (November 12, 2025)
- Lincoln, Nebraska (July 10, 2026)
- Zurich, Switzerland (July 10, 2026)
- Therapeutic Modalities (October 22, 2026)
- Monoclonal Antibodies (October 22, 2026)
- Cell Therapy (October 22, 2026)
- Drug Conjugates (October 22, 2026)
- Small Molecule Therapeutics (October 22, 2026)
- Nucleic Acid Therapeutics (NATs) (October 22, 2026)
- Anti-Drug Antibody (ADA) Assays (October 22, 2026)
- Neutralizing Antibody (NAb) Assays (October 22, 2026)
- Cellular Immunogenicity (October 22, 2026)
- PBMC Processing Services (October 22, 2026)
- Automation (October 22, 2026)
- Data Management & Biometric Services (November 12, 2025)
- Early Phase Clinical Services (November 12, 2025)
- Expertise (November 12, 2025)
- Therapeutic Expertise Areas (November 13, 2025)
- Biosimilar Clinical Research (November 13, 2025)
- Renal & Hepatic Impairment Studies (November 13, 2025)
- Cardiovascular Safety & Efficacy Trials (November 13, 2025)
- Tobacco Harm Reduction Studies (November 13, 2025)
- Regulatory Product Labeling Studies (November 13, 2025)
- Innovations (November 12, 2025)
- ClinQuick®: Rapid Clinical Trial Execution (November 13, 2025)
- Celexus®: Real-Time Data Capture (November 13, 2025)
- ECG Core Lab for Cardiac Trials (November 13, 2025)
- E-Lab Notebook: Digital Lab Data Management (November 13, 2025)
- Electronic Data Capture (EDC) Systems (November 13, 2025)
- Electronic Trial Master File (eTMF) System (November 13, 2025)
- Resources (November 12, 2025)
- The Future of Pharmacy (November 12, 2025)
- Careers (November 19, 2025)
- Investigators (December 17, 2025)
- Rifampin Alternatives for DDI Studies in Response to Nitrosamine Impurities (February 4, 2026)
- Bioanalytical Assays (July 9, 2026)
- Tobacco Assays (July 9, 2026)
- ACCP 2026 Session Slides (September 23, 2026)
- Sitemap (November 20, 2026)
